News

Life Sciences

AVEO Oncology Shows Positive Phase 3 Results in Renal Cell Carcinoma

Edward Kim | Equities.com |

Tivozanib showed 44% improvement in progression free survival and 26% reduction in risk of progression or death compared to sorafenib (Image: AVEO Pharmaceuticals)


Infinity Pharmaceuticals Expands Clinical Collaboration with Bristol-Myers Squibb to Urothelial Cancer

Edward Kim | Equities.com |

Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)


How Artificial Intelligence is Transforming Clinical Trial Recruitment

Visual Capitalist | Equities.com |

Poor clinical trial recruitment can cause losses up to $8 million each day. How can health and pharma companies get better at finding the right patients?


Aquestive Gets FDA Approval for Oral Film Formulation of Clobazam for LGS Seizures

Edward Kim | Equities.com |

First oral film formulation of clobazam, for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (Image: Aquestive Therapeutics)


Denali Therapeutics Signs Neurodegenerative and Inflammatory Disease Collaboration with Sanofi

Edward Kim | Equities.com |

$125 million upfront + potentially over $1 billion in milestone payments to develop RIPK1 inhibitors (Image: Denali Therapeutics)


Tango Therapeutics Signs Immuno-Oncology Collaboration with Gilead

Edward Kim | Equities.com |

$50 million upfront + up to $1.7 billion in milestone payments (Image: Tango Therapeutics)


Orchard Therapeutics' $200 Million IPO Expected This Week for Gene Therapy Programs

Edward Kim | Equities.com |

Autologous gene therapy for rare diseases including primary immune deficiencies, inherited metabolic disorders and blood disorders (Image: Orchard Therapeutics).


Dicerna Signs Potential Multi Billion Dollar Licensing and Research Deal with Lilly

Edward Kim | Equities.com |

$100 million upfront + $100 million in equity + up to $350 million in milestone payments per target for at least 10 targets (Image: Dicerna Pharmaceuticals)


Twist Bioscience's $75 Million IPO Expected Next Week for Gene Synthesis Platform

Edward Kim | Equities.com |

"Writing" synthetic DNA on silicon chips. Synthetic biology products market expected to grow to $13.9 billion by 2022 (Image: Twist Bioscience)


Shionogi and Roche Get FDA Approval for First New Flu Drug in Nearly 20 Years

Edward Kim | Equities.com |

New oral treatment to supplement vaccination, which remains the primary means of flu prevention (Image: CBS News)


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup

Equities.com Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.